Literature DB >> 26693838

Galectin-3 and Hypertensive Heart Disease.

Cesare Cuspidi1,2, Marijana Tadic3, Carla Sala4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26693838      PMCID： PMC8031644          DOI： 10.1111/jch.12756

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  16 in total

Review 1.  Hypertensive myocardial fibrosis.

Authors:  Cesare Cuspidi; Michele Ciulla; Alberto Zanchetti
Journal:  Nephrol Dial Transplant       Date:  2005-11-01       Impact factor: 5.992

2.  Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure.

Authors:  Tariq Ahmad; Mona Fiuzat; Benjamin Neely; Megan L Neely; Michael J Pencina; William E Kraus; Faiez Zannad; David J Whellan; Mark P Donahue; Ileana L Piña; Kirkwood F Adams; Dalane W Kitzman; Christopher M O'Connor; G Michael Felker
Journal:  JACC Heart Fail       Date:  2014-06       Impact factor: 12.035

Review 3.  Review of the prognostic value of galectin-3 in heart failure focusing on clinical utility of repeated testing.

Authors:  Francisco Javier Carrasco-Sánchez; María Inmaculada Páez-Rubio
Journal:  Mol Diagn Ther       Date:  2014-12       Impact factor: 4.074

4.  Independent associations of circulating galectin-3 concentrations with aortic pulse wave velocity and wave reflection in a community sample.

Authors:  Elena Libhaber; Angela J Woodiwiss; Andrew Raymond; Monica Gomes; Muzi J Maseko; Pinhas Sareli; Gavin R Norton
Journal:  Hypertension       Date:  2015-03-30       Impact factor: 10.190

5.  Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.

Authors:  Jennifer E Ho; Chunyu Liu; Asya Lyass; Paul Courchesne; Michael J Pencina; Ramachandran S Vasan; Martin G Larson; Daniel Levy
Journal:  J Am Coll Cardiol       Date:  2012-08-29       Impact factor: 24.094

6.  The fibrosis marker galectin-3 and outcome in the general population.

Authors:  R A de Boer; D J van Veldhuisen; R T Gansevoort; A C Muller Kobold; W H van Gilst; H L Hillege; S J L Bakker; P van der Harst
Journal:  J Intern Med       Date:  2011-11-18       Impact factor: 8.989

7.  Increased extracellular volume and altered mechanics are associated with LVH in hypertensive heart disease, not hypertension alone.

Authors:  Sujith Kuruvilla; Rajesh Janardhanan; Patrick Antkowiak; Ellen C Keeley; Nebiyu Adenaw; Jeremy Brooks; Frederick H Epstein; Christopher M Kramer; Michael Salerno
Journal:  JACC Cardiovasc Imaging       Date:  2015-01-07

8.  Structural myocardial alterations in diabetes and hypertension: the role of galectin-3.

Authors:  Jelena P Seferovic; Nebojsa M Lalic; Federico Floridi; Milorad Tesic; Petar M Seferovic; Vojislav Giga; Katarina Lalic; Aleksandra Jotic; Snezana Jovicic; Emina Colak; Gerardo Salerno; Patrizia Cardelli; Salvatore Di Somma
Journal:  Clin Chem Lab Med       Date:  2014-10       Impact factor: 3.694

9.  Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon.

Authors:  H L Schoeppner; A Raz; S B Ho; R S Bresalier
Journal:  Cancer       Date:  1995-06-15       Impact factor: 6.860

10.  Galectin-3 Predicts Left Ventricular Remodeling of Hypertension.

Authors:  Yongwei Yao; Dongli Shen; Rong Chen; Chunyang Ying; Chenghua Wang; Junfang Guo; Guohui Zhang
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-12-22       Impact factor: 3.738
View more
  1 in total

1.  Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients.

Authors:  Da-Jun Hu; Jing Xu; Wei Du; Jian-Xin Zhang; Min Zhong; Ya-Nan Zhou
Journal:  Int J Cardiovasc Imaging       Date:  2016-08-26       Impact factor: 2.357
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.